Abstract Homozygous and compound heterozygous MUTYH mutations predispose for MUTYH-associated polyposis (MAP). The clinical phenotype of MAP is characterised by the multiple colorectal adenomas and colorectal carcinoma. We previously found that female MAP patients may also have an increased risk for breast cancer. Yet, the involvement of MUTYH mutations in families with both breast cancer and colorectal cancer is unclear. Here, we have genotyped the MUTYH p.Tyr179Cys, p.Gly396Asp and p.Pro405Leu founder mutations in 153 Dutch families with breast cancer patients and colorectal cancer patients. Families were classified as polyposis, revised Amsterdam criteria positive (FCRC-AMS positive), revised Amsterdam criteria negative (FCRC-AMS negative), hereditary breast and colorectal cancer (HBCC) and non-HBCC breast cancer families. As anticipated, biallelic MUTYH mutations were identified among 13% of 15 polyposis families, which was significantly increased compared to the absence of biallelic MUTYH mutations in the population (P = 0.0001). Importantly, six heterozygous MUTYH mutations were identified among non-polyposis families with breast and colorectal cancer. These mutations were identified specifically in FCRC-AMS negative and in HBCC breast cancer families (11% of 28 families and 4% of 74 families, respectively; P = 0.02 for both groups combined vs. controls). Importantly, the 11% MUTYH frequency among FCRC-AMS negative families was almost fivefold higher than the reported frequencies for FCRC-AMS negative families unselected for the presence of breast cancer patients (P = 0.03). Together, our results indicate that heterozygous MUTYH mutations are associated with families that include both breast cancer patients and colorectal cancer patients, independent of which tumour type is more prevalent in the family.
Introduction
Germline mutations in the base excision repair gene MUTYH are associated with the recessively inherited colorectal cancer syndrome MUTYH-associated polyposis (MAP) that is characterised by multiple colorectal adenomas and colorectal carcinoma [1] [2] [3] [4] . Homozygous and compound heterozygous MUTYH mutations have been identified in about 25% of patients with polyposis [5, 6] . Two prevalent MUTYH mutations, c.536A [ G, p.Tyr179Cys, and c.1187G [ A, p.Gly396Asp (previously annotated as c.494A [ G, p.Tyr165Cys and c.1145G [ A, p.Gly382Asp, see ''Patients and methods'' section), account for approximately 75% of the reported mutations in MAP patients thus far [5] . In addition, several other MUTYH founder mutations have been identified, including the Dutch MUTYH c.1214C [ T, p.Pro405Leu founder mutation (previously c.1172C [ T, p.Pro391Leu) [6] . Together, the MUTYH p.Tyr179Cys, p.Gly396Asp and p.Pro405Leu mutations represent approximately 90% of MUTYH mutations reported in Dutch MAP patients [6, 7] .
The clinical phenotype associated with MAP overlaps with the familial adenomatous polyposis (FAP) and attenuated familial adenomatous polyposis (AFAP) phenotypes [5, 8] . The number of colorectal adenomas in MAP patients ranges from five to a few hundreds, generally presenting during the 5th decade of life. About half of MAP patients presents with colorectal cancer at the time of diagnosis [5, 8, 9] . In addition, germline MUTYH mutations have been identified in colorectal cancer patients with a cancer phenotype more reminiscent to Lynch syndrome (also known as hereditary non-polyposis colorectal cancer) [10] [11] [12] [13] [14] [15] [16] . Recently, we have identified a relatively high prevalence of breast cancer (18%) among Dutch female biallelic MUTYH mutation carriers, suggesting that breast cancer may be part of the clinical phenotype associated with MAP [6] . However, a recent Canadian study did not detect an association between MUTYH mutations and an increased breast cancer risk [17] . Here, we have evaluated whether MUTYH mutations predispose to breast cancer in the context of familial colorectal cancer, by screening the MUTYH p.Tyr179Cys, p.Gly396Asp and p.Pro405Leu founder mutations in 153 Dutch families with both breast cancer patients and colorectal cancer patients.
Patients and methods

Cancer family and population control cohorts
The 153 families with both breast cancer and colorectal cancer included in this study were ascertained by two academic cancer centres in the South-Western Netherlands:
Leiden University Medical Centre (LUMC) in Leiden and Erasmus University Medical Centre (Erasmus MC) in Rotterdam. The LUMC cohort included 37 cancer families selected from 565 non-BRCA1/BRCA2 breast cancer families and 46 cancer families selected from 311 colorectal cancer families without a mismatch repair gene defect and/ or a germline APC mutation, after molecular genetic screening according to Hendriks et al. [18] . The selected 83 LUMC cancer families each had at least one breast cancer patient and at least one colorectal cancer patient within second degree relatives (DGRs) and were registered by either the Clinical Genetic Centres of Leiden and Rotterdam, or the Dutch Foundation for Detection of Hereditary Tumors (STOET). The Erasmus MC cohort included 70 breast cancer families with hereditary breast and colorectal cancer (HBCC) as defined by Meijers-Heijboer et al. ([19] , and below). Germline BRCA1 and BRCA2 mutations were identified in 14 and 3 of these 70 HBCC breast cancer families, respectively. The Erasmus MC cohort was selected from 578 breast cancer families registered by the Rotterdam Family Cancer Clinic at Erasmus MC [19, 20] .
The 153 selected breast and colorectal cancer families were classified in six categories ( Table 1, Supplementary  Table 1) , including families with: 1, polyposis; 2, colorectal cancer and positive for the revised Amsterdam criteria (FCRC-AMS positive); 3, colorectal cancer and negative for the revised Amsterdam criteria (FCRC-AMS negative); 4, HBCC; 5, non-HBCC breast cancer and 6, mixed families with breast and colorectal cancer that could not be assigned to any of these five categories. In order to assign each family to only a single category of families, the six categories were ranked with the highest rank assigned to category 1. Families were classified as polyposis families (n = 15) when at least one patient in the family was diagnosed with many colorectal adenomas (more than 15, n = 2) or when at least two patients in the family were diagnosed with an unknown number of colorectal adenomas (n = 13). Families were classified as FCRC-AMS positive (n = 8) when they included at least three relatives with a Lynch syndrome-associated tumour (colorectal, small bowel, endometrial, ureter or renal pelvis) and one patient was a first DGR of the other two, and two successive generations were affected and one patient was diagnosed before age 50 years (revised Amsterdam criteria, [21] ). Families were classified as FCRC-AMS negative (n = 28) when they did not fulfil the revised Amsterdam criteria but included at least two colorectal cancer patients in first DGRs of whom at least one was diagnosed before age 50 years (n = 13) or at least three colorectal cancer patients of whom at least one is a first DGR of the other colorectal cancer patients (n = 15). Families were classified as HBCC families (n = 74) when they fulfilled the breast cancer family criterion and in addition included at least one patient with breast and colorectal cancer, or at least one patient with colorectal cancer diagnosed before age 50 years who is within second DGR of a breast cancer patient or at least two colorectal cancer patients of whom at least one is within second DGR of a breast cancer patient [19] . Non-HBCC breast cancer families (n = 13) included at least two-first or second DGRs with breast cancer of whom at least one was diagnosed before age 60 years. Fifteen families could not be classified according to any of these criteria. On average these 15 ''mixed'' families included 2 colorectal cancer patients and 1 breast cancer patient.
The 1,192 population controls originated mainly from the South-Western Netherlands and included a hospitalbased cohort of 165 spouses of members from breast cancer families, a hospital-based cohort of 254 individuals screened for non-cancer related genetic diseases and a population-based cohort of 773 randomly selected blood donors.
The Medical Ethical Review Boards of Leiden University Medical Centre and Erasmus University Medical Centre have approved this study and informed consent had been obtained from all patients.
MUTYH mutation analysis
MUTYH (ENSG00000132781) mutations were annotated according to the most up-to-date MUTYH annotation (www. lovd.nl/MUTYH and NM_001128425.1, http://www.ncbi. nlm.nih.gov/nuccore/190358496). The two most common MUTYH founder mutations p.Tyr179Cys and p.Gly396Asp as well as the Dutch MUTYH p.Pro405Leu founder mutation (previously known as p.Tyr165Cys, p.Gly382Asp and p.Pro391Leu, respectively) were screened in blood-derived DNA of the index patient from each cancer family. In the majority of families, the index patient was the breast cancer or colorectal cancer patient with the youngest age at diagnosis for whom DNA was available. MUTYH p.Tyr179Cys, p.Gly396Asp and p.Pro405Leu mutation screening included amplification of exons 7 (p.Tyr179Cys) and 13 (p.Gly396Asp and p.Pro405Leu) of the MUTYH gene by standard PCR as described [6, 7, 22] . Amplified fragments were subsequently sequenced with BigDye TM Terminator v3.0 or v3.1 Ready Reaction Cycle mix (Applied Biosystems) and analysed on an ABI-3100 or 3730 capillary sequencer. Analysis of the sequence data was performed using SeqScape software (Applied Biosystems) or Mutation Surveyor TM software (SoftGenetics, LLC). The MUTYH p.Tyr179Cys, p.Gly396Asp and p.Pro405Leu mutation frequencies in the control cohorts were determined by three mutation-specific Taqman Ò assays designed by Assays-bydesign SM Service (Applied Biosystems). Samples were run on an ABI-7500 Analyzer, and allelic discrimination was performed using SDS software (Applied Biosystems). No differences were identified for 238 genotypes that had been screened by Taqman analysis and sequencing, indicating that the sensitivity for detection of MUTYH mutations is similar for both techniques. All mutant MUTYH p.Tyr179-Cys, p.Gly396Asp and p.Pro405Leu samples were confirmed by analysis of an independently generated template. For the six heterozygous MUTYH mutation carriers, the (Tables 1, 2) . The index patient from family 20090 was diagnosed with colorectal cancer at age 40 years. DNA of two first-degree affected family members was available for additional MUTYH genotyping, revealing that the mother of the index patient (diagnosed with colorectal cancer at age 81 years) was a heterozygous MUTYH p.Tyr179Cys carrier and a brother of the index patient (diagnosed with colorectal cancer and adenomas at age 50 years) was a compound heterozygous MUTYH p.Tyr179Cys and p.Pro405Leu carrier. The index patient from family 53119 was diagnosed with colorectal cancer and adenomas at age 46 years. DNA from one first-degree affected family member was available for additional MUTYH genotyping, revealing that a sister of the index patient (diagnosed with breast cancer at age 63 years) carried a heterozygous MUTYH p.Tyr179Cys mutation (Table 2) . Together, 2 of 15 (13.3%) polyposis families carried compound heterozygous pathogenic MUTYH mutations as compared to none of 1,192 population controls (P = 0.0001; Table 1 ). Previous reports had identified homozygous and compound heterozygous MUTYH mutations in approximately 10% of FAP patients and in 20-5% of AFAP patients [3, 6, 24] . Our results are in line with these reports and hence confirm the reported association of biallelic MUTYH mutations with a polyposis phenotype.
Heterozygous MUTYH mutations in non-polyposis families with breast and colorectal cancer Heterozygous MUTYH mutations were identified in 3 of 28 (10.7%) FCRC-AMS negative families, including two families with index patients carrying the MUTYH p.Gly396Asp mutation and one family carrying MUTYH p.Pro405Leu (Tables 1, 2 ). Of these three FCRC-AMS negative families, family 50483 was classified as FCRC-AMS negative because it included two colorectal cancer patients in first DGRs of whom one was diagnosed before age 50 years, whereas families 10075 and 54058 included at least three colorectal cancer patients of whom at least one was a first DGR of the other colorectal cancer patients. DNA of non-index cases from two families (10075 and 50483) was available for additional genotyping. Yet, no MUTYH mutations were identified among the three breast cancer patients and the single patient with breast cancer and vulva melanoma ( Table 2 ). The 10.7% heterozygous MU-TYH mutation frequency among FCRC-AMS negative families was significantly increased compared to the 1.9% heterozygous MUTYH mutation frequency among controls (Table 1 ; P = 0.02) and was also higher than the absence of mutations among the nine FCRC-AMS positive families. Thus far, seven studies have evaluated MUTYH in familial colorectal cancer patients who did not fulfil the revised Amsterdam and/or Bethesda criteria, together including 866 cases [10] [11] [12] [13] [14] [15] [16] . The heterozygous MUTYH mutation frequencies ranged from 0 to 5.7%, with an average MUTYH mutation frequency of 2.3% (20/866). Thus, the reported MUTYH mutation frequency among such colorectal cancer families is about fivefold lower than we have observed among our FCRC-AMS negative families (2.3 vs. 10.7%; P = 0.03). In contrast to the earlier reported FCRC-AMS negative families, we have selected FCRC-AMS negative families that included at least one breast cancer patient. It seems plausible that the dissimilarity in MUTYH mutation frequency reflects this difference in selection criteria, suggesting that women with heterozygous MUTYH mutations from families that classify as FCRC-AMS negative are at increased risk for breast cancer.
The MUTYH p.Tyr179Cys, p.Gly396Asp and p.Pro405-Leu mutations were each identified once among the 74 HBCC families (Tables 1, 2) . Two of the MUTYH HBCC families (57466 and 59168) classified as HBCC families because they included a colorectal cancer patient diagnosed before age 50 years. HBCC family 15138 included two colorectal cancer patients of whom one was a first DGR of a breast cancer patient. DNA of non-index cases was available only for family 57466, revealing that a sister of the index patient (diagnosed with breast cancer at age 46 years) did not carry the MUTYH p.Tyr179Cys mutation (Table 2) . Together, 3 of the 74 (4.1%) HBCC families carried heterozygous MUTYH mutations, which was higher but not significantly different from the 1.9% population frequency (Table 1) . However, it is important to realise that our classification method by ranking allowed assignment of families to only a single category. As a result, families that fulfilled the criteria for both FCRC-AMS negative and HBCC were classified as FCRC-AMS negative families. Indeed, 17 of 28 FCRC-AMS negative families (61%) also met the HBCC criteria, as also four families from other categories. Moreover, 2 of the 17 FCRC-AMS negative families carried MUTYH mutations. In total, 5 of the 95 (5.3%) HBCC families were heterozygous MUTYH mutant which was increased compared to controls (P = 0.05; Supplementary Table 1 ), suggesting that MUTYH mutations also associate with HBCC. In order to further evaluate the involvement of heterozygous MUTYH mutations with HBCC, we re-classified all non-polyposis families according to the number of breast cancer and colorectal cancer patients in the family, resulting in three categories with more, equal or less colorectal cancer than breast cancer patients (Table 3 ). This analysis showed that the MUTYH mutation frequency is increased among families with more colorectal cancer than breast cancer patients (7.1%) as also among families with more breast cancer than colorectal cancer patients (5.8%), and that these frequencies were rather similar. In conclusion, our analyses suggest that heterozygous MUTYH mutations are associated with a breast and colorectal cancer phenotype, even though there was incomplete co-segregation of MUTYH mutations with breast cancer (Table 2 ). Heterozygous MUTYH mutations were identified specifically in families that classified as FCRC-AMS negative and HBCC. Importantly, the families may present with more colorectal cancer patients than breast cancer patients or vice versa. Also, the incomplete segregation between heterozygous MUTYH mutations with the cancer phenotype and the rather low cancer risks associated with these heterozygous MUTYH mutations (RR = *2.0) may suggest an as yet unrecognized low-risk polygenic disease mechanism [25] . More research is required to confirm our results in larger series but particularly to more precisely define the clinical criteria for the MUTYH-associated breast and colorectal cancer phenotype. Cancer families were classified into three categories, including families with at least two more colorectal cancer patients than breast cancer patients (CRC patients [ BRC patients), families with equal numbers (plus or minus one) of colorectal cancer patients and breast cancer patients (CRC patients = BRC patients) and families with at least two more breast cancer patients than colorectal cancer patients (CRC patients \ BRC patients)
